Clenbuterol, a beta(2)-adrenoceptor agonist, improves locomotor and histological outcomes after spinal cord contusion in rats

• Published in: Experimental neurology Vol. 159; no. 1; pp. 267 - 273
• Main Authors: Zeman, R J, Feng, Y, Peng, H, Etlinger, J D
• Format: Journal Article
• Language: English
• Published: United States 01.09.1999
• Subjects: Adrenergic beta-Agonists - pharmacology; Animals; Behavior, Animal - drug effects; Clenbuterol - pharmacology; Contusions - drug therapy; Contusions - pathology; Female; Locomotion - drug effects; Nerve Fibers, Myelinated - pathology; Rats; Rats, Wistar; Space life sciences; Spinal Cord - pathology; Spinal Cord Injuries - drug therapy; Spinal Cord Injuries - pathology; Wound Healing
• ISSN: 0014-4886
• DOI: 10.1006/exnr.1999.7146

An important goal of rehabilitation following spinal cord injury is recovery of locomotor function and muscular strength. In the present studies, we determined whether the beta(2)-agonist, clenbuterol, can improve recovery of locomotor function following spinal cord injury. A model of spinal cord injury was examined in which four graded levels of contusion injury were produced in rats at the level of T10 with a weight-drop device. Locomotor recovery was determined with the Basso, Beattie, and Bresnahan (BBB) scale, which distinguishes between 22 progressive levels of recovery. As observed previously, recovery during the 6 weeks following injury was inversely related to the severity of injury. However, clenbuterol caused substantial enhancement of recovery of locomotor function at the two most severe levels of injury (BBB scores 10-12 vs 2-4). In addition, the extent of recovery was directly related to sparing of spinal cord tissue at the contusion center in both untreated and clenbuterol-treated spinal cords. Optimization of beta(2)-agonist treatment may lead to a useful therapeutic modality for treatment of spinal cord contusion injury.